Notes from the Floor: Bloom Burton & Co., Day 1

Biotech Investing
Biotech Investing

The Bloom Burton & Co. Healthcare Investor Conference runs from May 2 to 3 in Toronto — here’s what happened on the first day of the show.

The Bloom Burton & Co. Healthcare Investor Conference is in full swing in Toronto, and the Investing News Network (INN) is on site to provide coverage.

Held from May 2 to May 3 at the Sheraton Center Hotel, the healthcare-focused event features around 60 Canadian publicly traded and venture-backed private companies, along with promising pre-venture companies.

INN spent the first day of the show attending presentations, as well as speaking with companies. Interviewees from day one include Antibe Therapeutics (TSXV:ATE), Zymeworks (TSX:ZYME,NYSE:ZYME), Knight Therapeutics (TSX:GUD), Crescita Therapeutics (TSX:CTX), Pediapharm (TSXV:PDP), Resverlogix (TSX:RVX) and Medicenna Therapeutics (TSX:MDNA). Scroll on for a pictorial overview of what happened on day one.

To kick off the day, Brian Bloom, co-founder, chairman and CEO at Bloom Burton & Co., took the stage to give his opening remarks.

This year is the seventh year that Bloom Burton & Co. has run its annual conference, and in his address Bloom explained that the event’s focus on investors is part of the reason for its success.

John Carroll of Endpoints News took over from Bloom to give the day’s keynote.

Presentations from over a dozen companies followed the talks from Bloom and Carroll, with midday bringing a lunch panel. Moderated by Bloom, the panelists were: Paulina Hill of Polaris Partners; Ting Jia of Hillhouse Capital; Daniel Krizek of Surveyor Capital; Stacey Seltzer of Aisling Capital; and Caroline Stout of EcoR1 Capital. All were able to share plenty of insight.

More company presentations followed in the afternoon, with attendees leaving the busy day tired but satisfied.

The Bloom Burton & Co. conference continues on May 3, and the INN team will be on the floor providing coverage. Check back at the end of the day for our recap of day two.

Don’t forget to follow us @INN_LifeScience for real-time updates!

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

The Conversation (0)